M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
AstraZeneca goes all-in on AbelZeta’s Car
A fresh licensing deal tidies up years of work between the two companies.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Innovent gives another cytokine a shot
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ArriVent moves to take on Rybrevant
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
J&J’s new trispecific play
JNJ-95566692 enters phase 1, with Qilu neck and neck.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
